Difference between revisions of "Paclitaxel (Taxol)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "manufacturer. Instead" to "manufacturer. Instead")
m
Line 7: Line 7:
  
 
==Diseases for which it is used==
 
==Diseases for which it is used==
 +
*[[Adenocarcinoma of unknown primary]]
 
*[[Basal cell carcinoma (BCC)]]
 
*[[Basal cell carcinoma (BCC)]]
 
*[[Bladder cancer]]
 
*[[Bladder cancer]]
Line 13: Line 14:
 
*[[Diffuse large B-cell lymphoma]]
 
*[[Diffuse large B-cell lymphoma]]
 
*[[Esophageal cancer]]
 
*[[Esophageal cancer]]
 +
*[[Gastric cancer]]
 
*[[Head and neck cancer]]
 
*[[Head and neck cancer]]
 
*[[Melanoma]]  
 
*[[Melanoma]]  
Line 19: Line 21:
 
*[[Penile cancer]]
 
*[[Penile cancer]]
 
*[[Prostate cancer]]
 
*[[Prostate cancer]]
−
*[[Soft tissue sarcoma]]
+
*[[SCC of unknown primary]]
 
*[[Small cell lung cancer]]
 
*[[Small cell lung cancer]]
 
*[[Testicular cancer]]
 
*[[Testicular cancer]]
 
*[[Thymoma]]
 
*[[Thymoma]]
−
*[[Unknown primary]]
 
 
*[[Uterine cancer]]
 
*[[Uterine cancer]]
 +
*[[Vascular sarcoma]]
  
 
==Patient drug information==
 
==Patient drug information==
Line 36: Line 38:
 
# First-line and subsequent therapy for the treatment of advanced [[Ovarian cancer | carcinoma of the ovary]]. As first-line therapy, Taxol is indicated in combination with [[Cisplatin (Platinol) | cisplatin]].
 
# First-line and subsequent therapy for the treatment of advanced [[Ovarian cancer | carcinoma of the ovary]]. As first-line therapy, Taxol is indicated in combination with [[Cisplatin (Platinol) | cisplatin]].
 
# The treatment of [[Breast cancer | breast cancer]] after failure of combination therapy for metastatic disease or relapsed within 6 months of adjuvant chemotherapy. Prior therapy should have included an [[:Category:Anthracyclines|anthracycline]] unless clinically contraindicated.
 
# The treatment of [[Breast cancer | breast cancer]] after failure of combination therapy for metastatic disease or relapsed within 6 months of adjuvant chemotherapy. Prior therapy should have included an [[:Category:Anthracyclines|anthracycline]] unless clinically contraindicated.
−
# The second-line treatment of AIDS-related [[Soft tissue sarcoma | Kaposi's sarcoma]].
+
# The second-line treatment of AIDS-related [[Vascular sarcoma | Kaposi's sarcoma]].
 
* 6/30/1998: New indication added: in combination with [[Cisplatin (Platinol) | cisplatin]], is indicated for the first-line treatment of [[Non-small cell lung cancer | non-small cell lung cancer]] in patients who are not candidates for potentially curative surgery and/or radiation therapy.
 
* 6/30/1998: New indication added: in combination with [[Cisplatin (Platinol) | cisplatin]], is indicated for the first-line treatment of [[Non-small cell lung cancer | non-small cell lung cancer]] in patients who are not candidates for potentially curative surgery and/or radiation therapy.
 
* 10/25/1999: New indication for the adjuvant treatment of node-positive [[Breast cancer | breast cancer]] administered sequentially to standard [[Doxorubicin (Adriamycin) | doxorubicin]]-containing combination chemotherapy.
 
* 10/25/1999: New indication for the adjuvant treatment of node-positive [[Breast cancer | breast cancer]] administered sequentially to standard [[Doxorubicin (Adriamycin) | doxorubicin]]-containing combination chemotherapy.
Line 48: Line 50:
 
|Anzatax
 
|Anzatax
 
|Anzatec
 
|Anzatec
−
|APO-Paclitaxel
 
 
|Asotax
 
|Asotax
 
|Betaxel
 
|Betaxel
 
|Bristaxol
 
|Bristaxol
 +
|Britaxol
 
|-
 
|-
−
|Britaxol
 
 
|Clitaxel
 
|Clitaxel
 
|Cytax
 
|Cytax
Line 61: Line 62:
 
|Ebetaxel
 
|Ebetaxel
 
|Formoxol
 
|Formoxol
 +
|Genaxol
 
|-
 
|-
−
|Genaxol
 
 
|Genetaxyl
 
|Genetaxyl
 
|Gros
 
|Gros
 
|Ifaxol
 
|Ifaxol
 
|Intaxel
 
|Intaxel
−
|LEP-ETU
 
−
|LI PU SU
 
 
|Magytax
 
|Magytax
−
|-
 
 
|Medixel
 
|Medixel
 
|Mitotax
 
|Mitotax
 
|Neotacs
 
|Neotacs
 +
|-
 
|Neotaxan
 
|Neotaxan
 
|Neotaxl
 
|Neotaxl
Line 79: Line 78:
 
|Oncotaxel
 
|Oncotaxel
 
|Onxol
 
|Onxol
−
|-
 
 
|Paclitax
 
|Paclitax
 
|Paclitaxel
 
|Paclitaxel
−
|Paclitaxel-GRY
+
|Paclitaxin
−
|Paclitaxel APS
 
−
|Paclitaxel Comp
 
−
|Paclitaxel Delta Farma
 
−
|Paclitaxel Ebewe
 
−
|Paclitaxel Hexal
 
 
|-
 
|-
−
|Paclitaxel Lens
 
−
|Paclitaxel Mayne
 
−
|Paclitaxel Microsules
 
−
|Paclitaxel Servycal
 
−
|Paclitaxin
 
 
|Pacliteva
 
|Pacliteva
 
|Pacxel
 
|Pacxel
 
|Padexol
 
|Padexol
−
|-
 
 
|Paklitaxfil
 
|Paklitaxfil
 
|Panataxel
 
|Panataxel
Line 103: Line 90:
 
|Paxene
 
|Paxene
 
|Paxenor
 
|Paxenor
 +
|-
 
|Paxus
 
|Paxus
 
|Petaxel
 
|Petaxel
 
|Phyxol
 
|Phyxol
−
|-
 
 
|Poltaxel
 
|Poltaxel
 
|Praxel
 
|Praxel
Line 112: Line 99:
 
|Sindaxel
 
|Sindaxel
 
|Taclipaxol
 
|Taclipaxol
 +
|-
 
|Tarvexol
 
|Tarvexol
 
|Taxocris
 
|Taxocris
 
|Taxodiol
 
|Taxodiol
−
|-
 
 
|Taxol
 
|Taxol
−
|Taxol Semi-Synthetic
 
 
|Taxomedac
 
|Taxomedac
 
|Taycovit
 
|Taycovit
−
|TE SU
 
−
|Teva-Paclitaxel
 
 
|Unitaxel
 
|Unitaxel
 
|Yewtaxan
 
|Yewtaxan
 
|-
 
|-
−
|ZI SU
 
 
|}
 
|}
 
==References==
 
==References==
Line 139: Line 122:
 
[[Category:Microtubule inhibitors]]
 
[[Category:Microtubule inhibitors]]
  
 +
[[Category:Adenocarcinoma of unknown primary medications]]
 
[[Category:Basal cell carcinoma (BCC) medications]]
 
[[Category:Basal cell carcinoma (BCC) medications]]
 
[[Category:Bladder cancer medications]]
 
[[Category:Bladder cancer medications]]
 
[[Category:Breast cancer medications]]
 
[[Category:Breast cancer medications]]
−
[[Category:Cancer of unknown primary medications]]
 
 
[[Category:Cervical cancer medications]]
 
[[Category:Cervical cancer medications]]
 
[[Category:Diffuse large B-cell lymphoma medications]]
 
[[Category:Diffuse large B-cell lymphoma medications]]
 
[[Category:Esophageal cancer medications]]
 
[[Category:Esophageal cancer medications]]
 +
[[Category:Gastric cancer medications
 
[[Category:Head and neck cancer medications]]
 
[[Category:Head and neck cancer medications]]
 
[[Category:Melanoma medications]]  
 
[[Category:Melanoma medications]]  
Line 152: Line 136:
 
[[Category:Penile cancer medications]]  
 
[[Category:Penile cancer medications]]  
 
[[Category:Prostate cancer medications]]
 
[[Category:Prostate cancer medications]]
−
[[Category:Soft tissue sarcoma medications]]  
+
[[Category:SCC of unknown primary medications]]
 
[[Category:Small cell lung cancer medications]]
 
[[Category:Small cell lung cancer medications]]
 
[[Category:Testicular cancer medications]]
 
[[Category:Testicular cancer medications]]
 
[[Category:Thymoma medications]]
 
[[Category:Thymoma medications]]
 
[[Category:Uterine cancer medications]]
 
[[Category:Uterine cancer medications]]
 +
[[Category:Vascular sarcoma medications]]
  
 
[[Category:Drugs FDA approved in 1992]]
 
[[Category:Drugs FDA approved in 1992]]
 
[[Category:PMDA approved drugs]]
 
[[Category:PMDA approved drugs]]
 
[[Category:WHO Essential Cancer Medicine]]
 
[[Category:WHO Essential Cancer Medicine]]

Revision as of 02:45, 24 January 2018

General information

Class/mechanism: Taxane, promotes assembly of microtubules, stablizes microtubules, preventing depolymerization. Paclitaxel interferes with the normal dynamic reorganization of microtubules that is necessary for regular interphase/mitosis processes. It also leads to creation of abnormal bundles of microtubules. Paclitaxel is highly lipophilic/insoluble in water and needs to be dissolved in Cremophor EL (polyoxyethylated castor oil), which may cause hypersensitivity infusion reactions.[1][2]
Route: IV
Extravasation: irritant (usually), vesicant (rare)

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

  • 12/29/1992: Initial FDA approval (label is not available)
  • 4/9/1998 (earliest label available on Drugs @ FDA): Indicated for:
  1. First-line and subsequent therapy for the treatment of advanced carcinoma of the ovary. As first-line therapy, Taxol is indicated in combination with cisplatin.
  2. The treatment of breast cancer after failure of combination therapy for metastatic disease or relapsed within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.
  3. The second-line treatment of AIDS-related Kaposi's sarcoma.
  • 6/30/1998: New indication added: in combination with cisplatin, is indicated for the first-line treatment of non-small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy.
  • 10/25/1999: New indication for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy.

Also known as

Synonyms
Abitaxel Altaxel Anzatax Anzatec Asotax Betaxel Bristaxol Britaxol
Clitaxel Cytax Daburex Dalys Drifen Ebetaxel Formoxol Genaxol
Genetaxyl Gros Ifaxol Intaxel Magytax Medixel Mitotax Neotacs
Neotaxan Neotaxl Ofoxel Oncotaxel Onxol Paclitax Paclitaxel Paclitaxin
Pacliteva Pacxel Padexol Paklitaxfil Panataxel Parexel Paxene Paxenor
Paxus Petaxel Phyxol Poltaxel Praxel Ribotax Sindaxel Taclipaxol
Tarvexol Taxocris Taxodiol Taxol Taxomedac Taycovit Unitaxel Yewtaxan

References

  1. ↑ 1.0 1.1 1.2 Paclitaxel (Taxol) package insert
  2. ↑ Paclitaxel (Taxol) package insert (locally hosted backup)
  3. ↑ Paclitaxel (Taxol) patient drug information (Chemocare)
  4. ↑ Paclitaxel (Taxol) patient drug information (UpToDate)

[[Category:Gastric cancer medications

Retrieved from "https://hemonc.org/w/index.php?title=Paclitaxel_(Taxol)&oldid=23293"